Hemodynamic effects of the serotonergic agent quipazine in the anesthetized dog

Vidrio, H.; Mena, M.A.

Drug Development Research 4(6): 647-654

1984


ISSN/ISBN: 0272-4391
DOI: 10.1002/ddr.430040607
Accession: 005557343

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
The hemodynamic effects of quipazine, a serotonergic agent, were determined in pentobarbital-anesthetized open-chest dogs administering the drug i.v. either by bolus injection or by continuous infusion. Bolus injections of 0.1 and 1 mg/kg elicited transient increases in blood pressure, peripheral resistance, aortic flow and stroke volume. Admimistration of 10 mg/kg decreased blood pressure, aortic flow, heart rate, cardiac contractility and venous pressure, and increased stroke volume. Infusion of quipazine at a rate of 0.5 mg/kg/min for 30 min initially increased blood pressure and peripheral resistance and subsequently produced hypotension and decreased cardiac function. From the beginning of infusion, heart rate and venous pressure decreased, while stroke volume increased. Pretreatment with methysergide antagonized the hypotension and bradycardia, as well as the changes in venous pressure and stroke volume. Quipazine apparently elicits complex, dose-related cardiovascular effects, some of which (hypotension, venodilatation and bradycardia) are mediated through methysergide-sensitive central serotonin receptors. The arterial vasoconstriction produced by low doses of the drug was not mediated through these receptors and was probably the result of activation of a cardiogenic reflex.

Hemodynamic effects of the serotonergic agent quipazine in the anesthetized dog